Search Subject Areas | Preprints.org

Preprint ARTICLE | doi:10.20944/preprints202404.1191.v1

Evaluation of Antitumor Activity of Reprogrammed Spleen CD8+ T-Cells in a Lewis Lung Cancer Mouse Model

Olga Pershina, Angelina Pakhomova, Natalia Ermakova, Edgar Pan, Evgenii G. Skurikhin, Darius Widera, Lubov Sandrikina, Lena Kogai, Mariia Zhukova, Vadim Zhdanov, Nikolai Kushlinskii, Sergey Morozov, Aslan Kubatiev, Alexander Dygai

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: reprogrammed spleen CD8+ T-cells; Lewis lung carcinoma; cancer stem cell; CD8+ and CD4+ T-cells; antimetastatic activity

Online: 18 April 2024 (14:22:11 CEST)

Show abstract| Download PDF| Supplementary Files| Share

Preprint COMMUNICATION | doi:10.20944/preprints202404.1066.v1

Development of Sensitive Anti-mouse CCR5 Monoclonal Antibodies Using the N-terminal Peptide Immunization

Rena Ubukata, Hiroyuki Suzuki, Tomohiro Tanaka, Tsunenori Ouchida, Guanjie Li, Mika K Kaneko, Yukinari Kato

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: mouse CCR5; monoclonal antibody; peptide immunization; flow cytometry; western blotting

Online: 18 April 2024 (09:29:28 CEST)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202403.1158.v2

Cancer Stem Cells, Loss of Function, and Stemness Recovery; Generation of New Functional Stem Cells in Cancer Cell Systems

Vladimir Niculescu

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: stem cell function; dysfunctionality; stress; DNA DSB; repair; genomic integrity

Online: 18 April 2024 (08:06:19 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.1167.v1

Discovery of Novel Potential Prognostic Marker and Targeted Therapy to Overcome Chemotherapy Resistance in an Advanced Stage Wilms’ Tumor

Pongsakorn Choochuen, Natakorn Nokchan, Natthapon Khongcharoen, Wison Laochareonsuk, Komwit Surachat, Thirachit Chotsampancharoen, Thanit Sila, Surasak Sangkhathat

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Wilms’ tumor; Chemotherapy resistance; Biomarkers; Somatic mutation; Targeted therapy; Cancer-driver mutation

Online: 17 April 2024 (15:03:01 CEST)

Show abstract| Download PDF| Supplementary Files| Share

Preprint ARTICLE | doi:10.20944/preprints202404.1138.v1

Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: an NCDB Analysis

Meghana Kesireddy, Lina Elsayed, Valerie K Shostrom, Priyal Agarwal, Samia Asif, Amulya Yellala, Jairam Krishnamurthy

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: metastatic triple negative breast cancer; overall survival; prognostic factors

Online: 17 April 2024 (12:01:26 CEST)

Show abstract| Download PDF| Share

Background: Metastatic triple-negative breast cancer (TNBC) is aggressive with a poor median overall survival (OS), ranging from 8 to 13 months. There exists considerable heterogeneity in the survival at the individual patient level. To better understand the survival heterogeneity and improve risk stratification, our study aims to identify the factors influencing survival utilizing a large patient sample in the National Cancer Database (NCDB). Methods: Women diagnosed with metastatic TNBC from 2010 to 2020 in the NCDB were included. Demographic, clinic-pathological, treatment data, and overall survival (OS) outcomes were collected. Kaplan-Meier curves were used to estimate OS. The log-rank test was used to identify OS differences between groups for each variable in the univariate analysis. For the multivariate analysis, the Cox proportional hazard model with backward elimination was used to identify factors affecting OS. Adjusted hazard ratios and 95% confidence intervals are presented. Results: 2,273 women had a median overall survival of 13.6 months. Factors associated with statistically significantly worse OS included older age, higher comorbidity scores, specific histologies, higher number of metastatic sites, presence of liver or other site metastases in those with only one metastatic site (excluding brain metastases), presence of cranial and extra-cranial metastases, lack of chemotherapy, lack of immunotherapy, lack of surgery to distant sites, lack of radiation to distant sites, and receipt of palliative treatment to alleviate symptoms. In the multivariate analysis, comorbidity score, histology, number of metastatic sites, immunotherapy, and chemotherapy had a statistically significant effect on the OS. Conclusions: Through NCDB analysis, we have identified prognostic factors for metastatic TNBC. These findings will help improve prognostication at diagnosis, optimize treatment strategies, and facilitate patient stratification in future clinical trials.

Preprint COMMUNICATION | doi:10.20944/preprints202404.1062.v1

Retrospective Analysis to Optimize the Detection of MET Exon 14 Skipping Mutations in Non-Small Cell Lung Cancer

Jang Jih Lu, Shu-Hui Tsai, Lee-Chung Lin, Tsung-Hsi Chueh

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: METex14; Oncomine Focus Assay; reverse transcription PCR

Online: 17 April 2024 (11:36:48 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.1118.v1

Polycyclic Aromatic Hydrocarbons (PAHs) in Grilled Marshmallows

Maciej Maciejczyk, Beata Janoszka, Magdalena Szumska, Beata Pastuszka, Sławomir Waligóra, Aleksandra Damasiewicz - Bodzek, Agnieszka Nowak, Krystyna Tyrpień-Golder

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: PAHs; marshmallows; chromatography

Online: 17 April 2024 (08:08:21 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.1044.v1

Real World Safety and Outcome of First Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study)

Alessandro Cafaro, Flavia Foca, Oriana Nanni, Marco Chiumente, Marina Coppola, Alberto Russi, Elena Svegliati, Paolo Baldo, Sabrina Orzetti, Fiorenza Enrico, Federico Foglio, Davide Pinnavaia, Vito Ladisa, Claudia Lauria Pantano, Rosa Lerose, Patrizia Nardulli, Simona Ferraiuolo, Piera Maiolino, Immacolata De Stasio, Federica Gradellini, Anna Rita Gasbarro, Rossella Santeramo, Gisella Carrucciu, Riccardo Provasi, Mario Cirino, Paola Cristina Cappelletto, Elisabetta Fonzi, Alessandra Pasqualini, Stefano Vecchia, Marianna Veraldi, Adele Emanuela De Francesco, Lucio Crinò, Angelo Delmonte, Carla Masini

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Pembrolizumab; Non-small cell lung cancer; real-world data; Immunotherapy; observational study

Online: 16 April 2024 (14:06:32 CEST)

Show abstract| Download PDF| Supplementary Files| Share

Preprint CASE REPORT | doi:10.20944/preprints202404.1067.v1

Intracranial Manifestation in Classical Hodgkin’s Lymphoma, Case Series and Review of the Literature

Karan Bir Singh, Krithika Muthyala, Daniel Pierotti, Brett Martin, Esther Morrison, Matthew Pearson, Omar Alkharabsheh

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Central nervous system (CNS) 1, intracranial lesion 2, Hodgkin lymphoma 3, relapse 4, refractory 5, neuroimaging 6, ring enhancing 7, immunotherapy 8, chemotherapy 9

Online: 16 April 2024 (14:00:25 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0982.v1

MiR-449a: A Potential Biomarker for Vocal Function Preservation in Combination Therapy for Laryngeal Cancer

Amal F. Gharib, Abdulraheem Almalki, Amani A. Alrehaili, Afaf Awwadh Alharthi, Ohud Alsalmi, Rasha L. Etewa, Mutaib M. Mashraqi, Shaimaa A Alharthi, Wael H Elsawy

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: laryngeal squamous cell carcinoma (lscc); chemotherapy; radiation therapy; mir-449a; biomarker

Online: 15 April 2024 (14:07:49 CEST)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202404.0950.v1

Bridging the Divide – a Review on the Implementation of Personalized Cancer Medicine

Michele Masucci, Ingemar Ernberg, Claes Karlsson, Lennart Blomqvist Blomqvist

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: individualised medicine; precision medicine; personalized medicine; stratified medicine; translational cancer research; cancer care; oncology; evidence based medicine; team science; management; scientific leadership; organization

Online: 15 April 2024 (10:45:33 CEST)

Show abstract| Download PDF| Share

Preprint BRIEF REPORT | doi:10.20944/preprints202404.0934.v1

Pentoxifylline and Norcantharidin Modify p62 Expression in 2D and 3D Cultures of B16F1 Cells

José Luis González-Quiroz, Juan Moisés Ocampo-Godínez, Victoria Noemi Hernández-González, Ruth Angélica Lezama, Elba Reyes-Maldonado, Armando Vega-López, María Lilia Domínguez-López

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Melanoma; 3D cultures; autophagy; p62; spheroids

Online: 15 April 2024 (10:20:48 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0867.v1

Stratification of Homologous Recombination Deficiency-Negative High-Grade Ovarian Cancer by the Type of Peritoneal Spread into Two Groups with Distinct Survival Outcome

Simon Schnaiter, Esther Schamschula, Juliane Laschtowiczka, Heidelinde Fiegl, Johannes Zschocke, Alain Zeimet, Katharina Wimmer, Daniel Reimer

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Personalized medicine; genomic instability; Miliary disease; epithelial ovarian cancer; PARP inhibitor; staging

Online: 12 April 2024 (21:20:09 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0765.v1

Circulating RKIP and pRKIP Might Be Novel Potential Biomarkers of Early-Stage Lung Cancer: Results from a Pilot Study

Roberto Gasparri, Massimo Papale, Angela Sabalic, Valeria Catalano, Annamaria Deleonardis, Federica De Luca, Elena Ranieri, Lorenzo Spaggiari

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: lung cancer; biomarkers; RKIP; pRKIP; urine; serum

Online: 11 April 2024 (14:13:13 CEST)

Show abstract| Download PDF| Share

Lung cancer remains the main cause of global cancer-related deaths. Currently low-dose computed tomography (LD-CT) shows a 20% reduction of mortality. However, its clinical suitability is hindered by cost, radiation, and some false positives. Thus, the discovery non-invasive and less-expensive biomarker is urgent needed. In this scenario, proteins released in biological fluids could be considered interesting biomarkers for their role in cancer development. We conducted a pioneering case-control pilot study aimed at assessing the usefulness of Raf Kinase Inhibitory Protein (RKIP) and its phosphorylated form (pRKIP) as potential early-stage lung cancer biomarkers. Urine and Blood samples of two consecutive and independent cohorts of lung cancer patients and healthy controls were screened by means of a novel experimental ELISA assay designed to evaluate both forms of the biomarker. Although urinary levels of RKIP were not statistically different between the lung cancer group and high-risk healthy group, serum ones instead increased significantly in early stage LC patients and permitted to discriminate LC patients from both low-risk (HS) and high-risk healthy subjects (HR-HS) with an overall 93% accuracy (AUC 0.93) when LC was compared to HS and 74% (AUC 0.73) when it was compared to high-risk group. Of note, the analysis of RKIP/pRKIP ratio also showed a high accuracy (90% - AUC 0.95) in discriminating LC patients from HS and more importantly, it allowed to identify LC patients compared to HR-HS, with a higher accuracy (79% - AUC 0.79) than RKIP alone. We hypothesize that serum RKIP levels may be correlated to the activation of the immune systems against the tumor during the first phases of its development. Our study identified a preliminary, non-invasive, RKIP and pRKIP profile able to discriminate with high specificity and sensitivity the early-stage lung cancer patients from high-risk Healthy Subjects. These results, although preliminary, suggest the utility of measuring RKIP/pRKIP as potential new screening test for lung cancer and provide the basis for future validation studies.

Preprint ARTICLE | doi:10.20944/preprints202404.0754.v1

What Is a Sarcoma ‘Specialist Center’? Multidisciplinary Research Finds an Answer

Roger L Wilson, Denise Reinke, Gerard van Oortmerssen, Ornella Gonzato, Gabriele Ott, Chandrajit P Raut, B Ashleigh Guadagnolo, Rick L.M. Haas, Jonathan Trent, Robin Jones, Lauren Pretorius, Brandi Felser, Mandy Basson, Kathrin Schuster, Bernd Kasper

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Sarcoma; specialist center; expert center; clinical expertise; patient advocacy; care pathways

Online: 11 April 2024 (12:59:06 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0719.v1

In silico Splicing Analysis of the PMS2 Gene: Exploring Alternative Molecular Mechanisms in PMS2-Associated Lynch Syndrome

Catalin Vasile Munteanu, Catalin Valer Marian, Adela Chirita-Emandi, Maria Puiu, Adrian Pavel Trifa

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Lynch syndrome; mismatch repair gene PMS2; alternative splicing; RNA splicing; splicing muta-tions; exon skipping; splicing regulatory elements

Online: 10 April 2024 (09:13:16 CEST)

Show abstract| Download PDF| Supplementary Files| Share

Preprint REVIEW | doi:10.20944/preprints202404.0689.v1

Updates on the Management of Colorectal Cancer in Older Adults

Conor DJ O’Donnell, Joleen Hubbard, Zhaohui Jin

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Colorectal cancer; Geriatric Oncology; Comprehensive Geriatric Assessment

Online: 10 April 2024 (07:59:50 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0680.v1

A Single Center Experience in Combined Oncological-Surgical Treatment for Resectable Locally-Advanced Non-small Cell Lung Cancer (NSCLC)

Dan Levy Faber, Abed Agbarya, Ben Caspy, Moshe Lapidot, Shoshana Keren Rosenberg, Sonia Shnair, Erez Sharoni, Ronen Galili

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Locally advanced stage; Neoadjuvant treatment; Non-Small Cell Lung Cancer, surgery; chemoradiation therapy, immunotherapy

Online: 9 April 2024 (14:16:17 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0636.v1

BRCA1/2 Testing Landscape in Ovarian Cancer: A Nationwide, Real-World Data Study

Lieke Lanjouw, Joost Bart, Marian J.E. Mourits, Stefan M. Willems, Annemieke H. van der Hout, Arja ter Elst, Geertruida H. de Bock

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: BRCA1/2 pathogenic variants; ovarian carcinoma; tumor test; next generation sequencing; real-world data

Online: 9 April 2024 (11:45:17 CEST)

Show abstract| Download PDF| Supplementary Files| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0651.v1

Dual Inhibition of PI3 Kinase and MAP Kinase Signaling Pathways in Intrahepatic Cholangiocellular Carcinoma Cell Lines Leads to Proliferation Arrest but Not Apoptosis

Jessica Schüler, Martina Vockerodt, Niloofar Salehzadeh, Jürgen Becker, Joerg Wilting

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Cholangiocyte – primary liver cancer – selumetinib – AZD6244 – MK2206 – intrahepatic cholangiocarcinoma

Online: 9 April 2024 (10:56:59 CEST)

Show abstract| Download PDF| Supplementary Files| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0571.v1

Unselective Measurement of Tumor‐to‐Stroma Proportion in Colon Cancer at the Invasion Front– an Elusive Prognostic Factor. Original Patient Data and Review of the Literature

Zsolt Fekete, Patricia Ignat, Amelia Cristina Resiga, Nicolae Todor, Alina-Simona Muntean, Liliana Resiga, Sebastian Curcean, Gabriel Lazar, Alexandra Gherman, Dan Eniu

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: fibrosis; tumor stroma; stroma to tumor ratio; pathology markers; colon cancer; adjuvant treatment; invasion front

Online: 8 April 2024 (14:35:27 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0320.v1

Sequential Evaluation of Hematology Markers as a Prognostic Factor in Glioblastoma Patients

João Meira Gonçalves, Bruno Carvalho, Rui Tuna, Patricia Polónia, Paulo Linhares

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Glioblastoma; Hematological markers; Non-invasive biomarkers; Neutrophil-to-Lymphocyte Ratio (NLR); Platelet-to-Lymphocyte Ratio (PLR); Red Blood Cell Distribution Width (RDW-CV)

Online: 3 April 2024 (16:31:38 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0261.v1

Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth and Lung Metastasis in a Triple Negative Breast Cancer Model

Lenore Monterroza, Maria M. Parrilla, Sarah G. Samaranayake, Dormarie E. Rivera-Rodriguez, Sung Bo Yoon, Ramireddy Bommireddy, Justin Hosten, Luisa Cervantes Barragan, Adam Marcus, Brian S. Dobosh, Periasamy Selvaraj, Rabindra Tirouvanziam

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: CD4+ T-cell; CD8+ T-cell; invasion; myeloid-derived suppressor cell; triple-negative breast cancer; tumor-infiltrating neutrophils

Online: 3 April 2024 (11:06:57 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0199.v1

In Silico Search for Drug Candidates Targeting the PAX8–PPARγ Fusion Protein in Thyroid Cancer

Kaori Sakaguchi, Yoshio Okiyama, Shigenori Tanaka

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: follicular thyroid neoplasia; PAX8– PPARγ fusion; fusion protein; structure-based drug design

Online: 3 April 2024 (07:24:16 CEST)

Show abstract| Download PDF| Supplementary Files| Share

Preprint CASE REPORT | doi:10.20944/preprints202404.0157.v1

Autoimmune Encephalitis Following Check Point Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission

Giuseppe Civardi, Alessia Medioli, Carlotta Braghieri, Massimo Ambroggi, Paolo Immovilli, Simone Orsucci, Paolo Contini, Giuseppe Aronica, Luigi Cavanna

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: autoimmune encephalitis; checkpoint inhibitor; melanoma; pembrolizumab; adverse event

Online: 2 April 2024 (16:18:10 CEST)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202404.0193.v1

Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies

Ahmed M. Mahmoud, Amr Moustafa, Carter Day, Mohamed E. Ahmed, Wael Zeina, Usama M. Marzouk, Spyridon Basourakos, Rimki Haloi, Mindie Mahon, Miguel Muniz, Daniel S. Childs, Jacob J. Orme, Irbaz Bin Riaz, A. Tuba Kendi, Bradley J. Stish, Brian J. Davis, Eugene D. Kwon, Jack R. Andrews

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Prostate Cancer; Lung Metastasis; Systemic Therapy; Metastasis-Directed therapy

Online: 2 April 2024 (10:26:09 CEST)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202404.0103.v1

Studying the Effect of Host Genetic Background of Juvenile Polyposis Development using Collaborative Cross and Smad4 Knock-out Mouse Models

Osayd Zohud, Kareem Midlej, Iqbal M. Lone, Aysar Nashef, Imad Abu El-naaj, FUAD A. IRAQI

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Juvenile Polyposis Syndrome; Smad4 knockout; Collaborative Cross; Host Genetic background.; Machine Learning

Online: 1 April 2024 (15:02:41 CEST)

Show abstract| Download PDF| Share

Preprint CASE REPORT | doi:10.20944/preprints202403.1661.v2

A Case Report of Acute Lymphoblastic Leukaemia (ALL)/Lymphoblastic Lymphoma (LBL) Following the Second Dose of Comirnaty®: An Analysis of the Potential Pathogenic Mechanism Based on of the Existing Literature

Patrizia Gentilini, Janci C. Lindsay, Nafuko Konishi, Masanori Fukushima, Panagis Polykretis

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: COVID-19 genetic vaccines; mRNA vaccines; adverse effects; lymphoblastic leukemia; lymphoblastic lymphoma

Online: 1 April 2024 (13:21:50 CEST)

Show abstract| Download PDF| Share

In this report we describe the case of a healthy, young, athletic woman who developed acute lymphoblastic leukaemia (ALL)/lymphoblastic lymphoma (LBL) after receiving the second dose of the Pfizer/BioNTech modified mRNA (modRNA) COVID-19 genetic vaccine (marketed as Comirnaty^®). The first dose of the genetic vaccine did not appear to illicit any noticeable side effects, but within 24 hours of the second dose the patient suffered widespread and intensifying bone pain, fever, vomiting, and general malaise. Due to the persistence of the symptoms, the patient underwent a series of tests and examinations including a full laboratory workup, a consult with a clinical immunologist and rheumatologist, a Positron Emission Tomography (PET) imaging, as well as an osteomedullary biopsy. These together led to a definitive diagnosis of ALL. A time interval of 16 weeks from the second vaccination to the diagnosis of cancer was noted. Several similar cases with identical pathology which developed after the modRNA COVID-19 vaccination, are described in case reports in the scientific literature. The massive and indiscriminate use of genetic vaccines to fight COVID-19 is raising serious concerns about their safety and about the technology platform as a whole for this purpose. Growing evidence is accumulating regarding the biodistribution and persistence of the modRNA which can reach, thanks to the lipid nanoparticles, a multitude of tissues and organs of the body, including the bone marrow and other blood-forming organs and tissues. Moreover, there is evidence that the modRNA vaccines display a particular tropism for the bone marrow, influencing the immune system at multiple levels and being able to trigger not only autoimmune-based pathologies, but also neoplastic mechanisms. The aim of this article is to assess, on the basis of the available scientific literature, the risk of developing haematopoietic cancers after modRNA vaccination, and to investigate the potential genetic mechanisms involved in the pathogenesis of disease.

Preprint ARTICLE | doi:10.20944/preprints202403.1824.v1

Dipeptidyl Peptidase 9 (DPP9) Depletion From Hepatocytes in Mice Retards Liver Tumour Growth and Increases Intrahepatic Caspase-1 Activation

Jiali Carrie Huang, Xinlin Linda Tong, Michelle Sui Wen Xiang, Badwi B. Boumelhem, Diarmid P Foulis, Mingchang Zhang, Catriona McKenzie, Geoffrey William McCaughan, Thomas Reinheckel, Hui Emma Zhang, Mark Douglas Gorrell

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: dipeptidyl peptidase 9; serine protease; hepatocellular carcinoma; inflammasome; autophagy; histopathology

Online: 29 March 2024 (08:34:13 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1579.v2

Activation of the Anaphase Promoting Complex Restores Impaired Mitotic Progression and Chemosensitivity in Multiple Drug Resistant Human Breast Cancer

Mathew Lubachowski, Cordell VanGenderen, Sarah Valentine, Zach Belak, Gerald Floyd Davies, Terra Gayle Arnason, Troy Anthony Alan Harkness

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Multiple Drug Resistant breast cancer; Anaphase Promoting Complex; cell culture; PDX mouse model

Online: 28 March 2024 (13:34:15 CET)

Show abstract| Download PDF| Supplementary Files| Share

The development of multiple drug resistant (MDR) cancer all too often signals the need for alternative toxic therapy or palliative care. Our recent in vivo and in vitro studies using canine MDR lymphoma cancer cells demonstrated that the Anaphase Promoting Complex (APC) is impaired in MDR cells compared to normal canine control and drug sensitive cancer cells. Here, we sought to establish whether this phenomena is a generalizable mechanism independent of species, malignancy type or chemotherapy regime. To test the association of blunted APC activity with MDR cancer behavior, we used matched parental and MDR MCF7 human breast cancer cells, and a patient derived xenograft (PDX) model of human breast cancer. We show that APC activating mechanisms, such as APC subunit 1 (APC1) phosphorylation and CDC27/CDC20 protein associations, are reduced in MCF7 MDR cells when compared to chemosensitive matched cell lines. Consistent with impaired APC function in MDR cells, APC substrate proteins failed to be effectively degraded. Similar to our previous observations in canine MDR lymphoma cells, chemical activation of the APC using Mad2 Inhibitor-1 (M2I-1) in MCF7 MDR cells enhanced APC substrate degradation and resensitized MDR cells in vitro to the cytotoxic effects of the alkylating chemotherapeutic agent, Doxorubicin (DOX). Using cell cycle arrest/release experiments we show that chemo-sensitive and -resistant MCF7 cells progress through the cell cycle at similar rates, but mitosis is delayed in MDR cells with elevated substrate levels. When treated with M2I-1, MDR cells progress through mitosis at a faster rate that coincides with reduced levels of APC substrates. In our PDX model, mice growing a clinically-MDR human breast cancer tumor show significantly reduced tumor growth when treated with M2I-1, with evidence of increased DNA damage and apoptosis. Thus, our results strongly support the hypothesis that APC impairment is a driver of aggressive tumor development and that targeting the APC for activation has the potential for meaningful clinical benefits in treating recurrent cases of MDR malignancy.

Preprint ARTICLE | doi:10.20944/preprints202403.1666.v1

Impact of SARS-CoV-2 (COVID-19) Pandemic on Characteristics and Management of Uveal Melanoma in National Referral Center in Poland

Bożena Romanowska-Dixon, Michał Szymon Nowak, Janusz Śmigielski, Magdalena Dębicka-Kumela

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: uveal melanoma; brachytherapy; proton therapy; enucleation

Online: 27 March 2024 (10:04:16 CET)

Show abstract| Download PDF| Share

Preprint CASE REPORT | doi:10.20944/preprints202403.1661.v1

A Case Report of Acute Lymphoblastic Leukaemia (ALL)/Lymphoblastic Lymphoma (LBL) Following the Second Dose of Comirnaty®: An Analysis of the Potential Pathogenic Mechanism Based on of the Existing Literature

Patrizia Gentilini, Janci C. Lindsay, Nafuko Konishi, Masanori Fukushima, Panagis Polykretis

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: COVID-19 genetic vaccines; mRNA vaccines; adverse effects; lymphoblastic leukemia; lymphoblastic lymphoma

Online: 27 March 2024 (08:34:34 CET)

Show abstract| Download PDF| Share

In this report we describe the case of a healthy, young, athletic woman who developed acute lymphoblastic leukaemia (ALL)/lymphoblastic lymphoma (LBL) after receiving the second dose of the Pfizer/BioNTech modified mRNA (modRNA) COVID-19 genetic vaccine (marketed as Comirnaty^®). The first dose of the genetic vaccine did not appear to illicit any noticeable side effects, but within 24 hours of the second dose the patient suffered widespread and intensifying bone pain, fever, vomiting, and general malaise. Due to the persistence of the symptoms, the patient underwent a series of tests and examinations including a full laboratory workup, a consult with a clinical immunologist and rheumatologist, a Positron Emission Tomography (PET) imaging, as well as an osteomedullary biopsy. These together led to a definitive diagnosis of ALL. A time interval of 16 weeks from the second vaccination to the diagnosis of cancer was noted. Several similar cases with identical pathology which developed after the modRNA COVID-19 vaccination, are described in case reports in the scientific literature. The massive and indiscriminate use of genetic vaccines to fight COVID-19 is raising serious concerns about their safety and about the technology platform as a whole for this purpose. Growing evidence is accumulating regarding the biodistribution and persistence of the modRNA which can reach, thanks to the lipid nanoparticles, a multitude of tissues and organs of the body, including the bone marrow and other blood-forming organs and tissues. Moreover, there is evidence that the modRNA vaccines display a particular tropism for the bone marrow, influencing the immune system at multiple levels and being able to trigger not only autoimmune-based pathologies, but also neoplastic mechanisms. The aim of this article is to assess, on the basis of the available scientific literature, the risk of developing haematopoietic cancers after modRNA vaccination, and to investigate the potential genetic mechanisms involved in the pathogenesis of disease.

Preprint REVIEW | doi:10.20944/preprints202403.1622.v1

Why Hydrogen Peroxide-Producing Proteins are not suitable Targets for Drug Development

Vehary Sakanyan, Rodolphe Alves de Sousa

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Reactive oxygen species; hydrogen peroxide; superoxide dismutase; epidermal growth factor receptor; redox therapy; cancer

Online: 27 March 2024 (07:52:45 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1579.v1

Activation of the Anaphase Promoting Complex Restores Impaired Mitotic Progression and Chemosensitivity in Multiple Drug Resistant Human Breast Cancer

Mathew Lubachowski, Cordell VanGenderen, Sarah Valentine, Zach Belak, Gerald Floyd Davies, Terra Gayle Arnason, Troy Anthony Alan Harkness

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Multiple Drug Resistant breast cancer; Anaphase Promoting Complex; cell culture; PDX mouse model

Online: 26 March 2024 (14:20:12 CET)

Show abstract| Download PDF| Supplementary Files| Share

The development of multiple drug resistant (MDR) cancer all too often signals the need for alternative toxic therapy or palliative care. Our recent in vivo and in vitro studies using canine MDR lymphoma cancer cells demonstrated that the Anaphase Promoting Complex (APC) is impaired in MDR cells compared to normal canine control and drug sensitive cancer cells. Here, we sought to establish whether this phenomena is a generalizable mechanism independent of species, malignancy type or chemotherapy regime. To test the association of blunted APC activity with MDR cancer behavior, we used matched parental and MDR MCF7 human breast cancer cells, and a patient derived xenograft (PDX) model of human breast cancer. We show that APC activating mechanisms, such as APC subunit 1 (APC1) phosphorylation and CDC27/CDC20 protein associations, are reduced in MCF7 MDR cells when compared to chemosensitive matched cell lines. Consistent with impaired APC function in MDR cells, APC substrate proteins failed to be effectively degraded. Similar to our previous observations in canine MDR lymphoma cells, chemical activation of the APC using Mad2 Inhibitor-1 (M2I-1) in MCF7 MDR cells enhanced APC substrate degradation and resensitized MDR cells in vitro to the cytotoxic effects of the alkylating chemotherapeutic agent, Doxorubicin (DOX). Using cell cycle arrest/release experiments we show that chemo-sensitive and -resistant MCF7 cells progress through the cell cycle at similar rates, but mitosis is delayed in MDR cells with elevated substrate levels. When treated with M2I-1, MDR cells progress through mitosis at a faster rate that coincides with reduced levels of APC substrates. In our PDX model, mice growing a clinically-MDR human breast cancer tumor show significantly reduced tumor growth when treated with M2I-1, with evidence of increased DNA damage and apoptosis. Thus, our results strongly support the hypothesis that APC impairment is a driver of aggressive tumor development and that targeting the APC for activation has the potential for meaningful clinical benefits in treating recurrent cases of MDR malignancy.

Preprint ARTICLE | doi:10.20944/preprints202403.1500.v1

Defucosylated Anti-CD44 Monoclonal Antibodies Exert Antitumor Activities against Esophageal Tumor Xenograft

Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, Akira Ohkoshi, Mika K Kaneko, Yukio Katori, Yukinari Kato

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: CD44; monoclonal antibody; ADCC; CDC; esophageal tumor; antitumor activity

Online: 26 March 2024 (08:14:10 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1496.v1

Evaluation of in silico tools and Chat-GPT in identifying the impact of missense variants of immune-related genes associated with immunotherapy outcomes for solid tumors

Yoonhee Choi, Chan Mi Jung, Grace Kang, Jessica Jooeun Jang, Lena Chae, Peter Haseok Kim, Pedro Hermida de Viveiros

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: solid tumor; Artificial intelligence; Variant classification; Pathogenicity; Variants of uncertain significance

Online: 26 March 2024 (02:45:01 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1473.v1

Uncovering Pathogenic Variants in Cancer Susceptibility Genes through Genetic Testing for Pancreatic Cancer Patients

Kevisa Potska, Anastasia Katseli, Konstantinos Agiannitopoulos, Christina Ntogka, Georgios N. Tsaousis, Nikolaos Tsoulos, Adina Emilia Croitoru, Dimitrios Ziogas, Maria Theochari, Christos Christodoulou, Epaminondas Samantas, Dimitrios Janninis, Ilias Athanasiadis, Angelos Koutras, Eirini Papadopoulou, Onder Kirca, Muharrem Okan Cakir, Gholam Hossein Ashrafi, George Nasioulas, Mustafa Ozdogan

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Hereditary; Pancreatic cancer; Next Generation Sequencing (NGS)

Online: 25 March 2024 (09:58:18 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1455.v1

GIPR Overexpression Reduces the Tumorigenic Potential of Retinoblastoma Cells

André Haase, Emily Alefeld, Fatma Yalinci, Dario Van Meenen, Maike Anna Busch, Nicole Dünker

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: retinoblastoma; RB; gastric inhibitory polypeptide receptor; GIPR; trefoil factor family peptide; TFF1; CAM; tumorigenesis; MK0893; miR5-542-5p

Online: 25 March 2024 (08:36:23 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint REVIEW | doi:10.20944/preprints202403.1401.v1

Plasma Metabolite Profiling in the Search for Early-Stage Biomarkers for Lung Cancer: Some Important Breakthroughs

Jill Meynen, Peter Adriaensens, Maarten Criel, Evelyne Louis, Karolien Vanhove, Michiel Thomeer, Liesbet Mesotten, Elien Derveaux

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: biomarkers; lung cancer; metabolomics; NMR (nuclear magnetic resonance)

Online: 25 March 2024 (07:06:46 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202308.1536.v5

A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations

Michael Renteln

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Multiregion sequencing; multisample sequencing; cell-free circulating tumor DNA; clonal mutations; Achilles Therapeutics; and OVERCOME

Online: 22 March 2024 (12:06:13 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1240.v1

Evolution of Complexity of Palliative Care Needs and Patient Profiles according to the PALCOM Scale: Pooled Analysis of the Cohorts for the Development and Validation of the PALCOM Scale in Advanced Cancer Patients

Albert Tuca, Margarita Viladot, Gemma Carrera, Lucia Llavata, Carmen Barrera, Manoli Chicote, Javier Marco-Hernández, Joan Padrosa, Carles Zamora-Martinez, Ignacio Grafia, Anais Pascual, Elena Font, Carme Font

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: early palliative care; advanced cancer; complexity of care needs; integration of palliative care in oncology; specialist palliative care; predictive model of complexity

Online: 21 March 2024 (12:23:36 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1257.v1

Zebrafish avatars: towards functional precision medicine in low-grade serous ovarian cancer

Charlotte Fieuws, Jan Willem Bek, Bram Parton, Olivier De Wever, Milena Hoorne, Marta F Estrada, Jo Van Dorpe, Hannelore Denys, Koen Van de Vijver, Kathleen B.M. Claes

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: ovarian cancers; zebrafish xenografts; functional precision medicine; zAvatars; low-grade serous

Online: 21 March 2024 (10:45:03 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1095.v1

KRAS Inhibitors Are Potential Prophylaxis for Colorectal Cancer Metachronous Metastasis

Yaoyu Guo, Chuling Hu, Guojie Long, Du Cai, Zhaoliang Yu, Xingxing Huang, Zerong Cai, Peishan Hu, Yufeng Chen, Feng Gao, Xiaojian Wu

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: KRAS inhibitor; metastasis; colorectal cancer; machine learning; meta analysis

Online: 21 March 2024 (03:50:20 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint REVIEW | doi:10.20944/preprints202403.1203.v1

Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer

Francesco Giulio Sullo, Alessandro Passardi, Chiara Gallio, Chiara Molinari, Giorgia Marisi, Eleonora Pozzi, Leonardo Solaini, Alessandro Bittoni

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: rectal cancer; total neoadjuvant treatment; immunocheckpoint inhibitors; nonoperative management; ctDNA.

Online: 20 March 2024 (16:08:21 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1229.v1

Role of Protein Tyrosine Phosphatase Receptor Type E (PTPRE) in Chemoresistant Retinoblastoma

Lars Mohren, Annika Doege, Natalia Miroschnikov, Oliver Dräger, Maike Anna Busch, Nicole Dünker

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: PTPRE; miR631; retinoblastoma; CAM assay; etoposide; chemoresistance; tumorigenesis

Online: 20 March 2024 (13:13:44 CET)

Show abstract| Download PDF| Share

Preprint BRIEF REPORT | doi:10.20944/preprints202403.1158.v1

The Life Cycle of Stemness Explained by Evolutionary Cancer Cell Biology (ECCB)

Vladimir Niculescu

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: stem cell function; dysfunctionality; stress; DNA DSB; repair; genomic integrity

Online: 20 March 2024 (12:28:51 CET)

Show abstract| Download PDF| Share

Preprint COMMUNICATION | doi:10.20944/preprints202403.1166.v1

C₈Mab-21: A Novel Anti-human CCR8 Monoclonal Antibody for Flow Cytometry

Tomohiro Tanaka, Hiroyuki Suzuki, Guanjie Li, Mika K Kaneko, Yukinari Kato

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: CCR8, CBIS method, monoclonal antibody, flow cytometry

Online: 19 March 2024 (14:41:05 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202403.1092.v1

Exploring the role of HPV: from Sexually transmitted infection to Oropharyngeal Cancers

Kritika Srinivasan Rajsri, Vaishnavi Rao, Sonaj Vardhman

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Human papillomavirus; sexually transmitted infection; oropharyngeal carcinoma; oral cancer; head and neck cancers

Online: 19 March 2024 (08:05:20 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1037.v1

Unveiling the Genomic Landscape of Intraductal Carcinoma of the Prostate Using Spatial Gene Expression Analysis

Ryuta Watanabe, Noriyoshi Miura, Mie Kurata, Riko Kitazawa, Tadahiko Kikugawa, Takashi Saika

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: spatial gene expression analysis; intraductal carcinoma of the prostate (IDCP); hypoxic markers; immune cells; tumor microenvironment

Online: 18 March 2024 (16:18:27 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.1058.v1

Mesothelioma Associated Fibroblasts Modulate the Response of Mesothelioma Patient Derived Organoids to Chemotherapy through Interleukin-6.

Mario Cioce, Veronica Gatti, Fabiana Napolitano, Noemi Maria Giorgiano, Andrea Marra, Giuseppe Portella, Alfonso Fiorelli, Francesca Pentimalli, Vito Michele Fazio

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Mesothelioma patient-derived organoids, PDO, IL-6, mesothelioma-associated fibroblasts; cocultures, cisplatin; pemetrexed; chemoresistance

Online: 18 March 2024 (15:17:01 CET)

Show abstract| Download PDF| Supplementary Files| Share

Background. Malignant pleural mesothelioma (MPM) is still a rather incurable disease. Many classes of compounds with various mechanisms of action have been tested in vivo and ex-vivo, with rather disappointing results. This is partly due to preclinical studies mostly performed in models that fail to recapitulate MPM complexity and do not retain the intra-tumor heterogeneity, a propelling force for tumor progression. Additionally, we and others have shown that, under stress-induced chemotherapy, profound rearrangements take place in MPM cultures to fuel the emergence of chemoresistant cell subpopulations. Thus, finding clinically actionable modulators of MPM resistance is still a very urgent need. Methods. Setup and propagation of patient-derived organoid cultures from MPM pleural effusions; flow cytometry-based validation of organoid cultures, isola-tion and propagation of mesothelioma-associated fibroblasts; co-cultures, Lu-minex-based Cytokine array, ELISA assay to quantitate IL-6 in the conditioned media, qRT-PCR to assess mRNA expression of cancer stem cell markers and fibroblast markers. Results. Organoid cultures were obtained from eight MPM patients by using specific growth media and conditions to propagate pleural effusion-derived cells. We proved that primary MPM specimens and serially passaged (mesothelio-ma-Patient-Derived-Organoids) mPDOs were cytologically similar, with the obtained mPDOs expressing mesothelial markers similarly to the originating specimen. As expected from a clinically relevant model, the size and number of mPDOs were altered, in a patient-specific way, when pharmacologically relevant doses of chemotherapy drugs were added. We derived Mesothelio-ma-Associated-Fibroblasts (MAFs) and the addition of MAFs, to various ratios, altered the response of the mPDOs to pemetrexed + cisplatin, toward a reduced sensitivity to the latter anticancer agents. Additionally, organoid formation and size were altered by MAF-conditioned media, and this correlated with increased expression of cancer stem cell markers. We showed increased levels of IL-6 in the media of the treated cocultures and showed that this latter was derived from the MAFs. Conclusions. Increased secretion of IL-6 by mesothelioma-associated fibroblasts (MAFs) contributes to the resistance of the MPM to therapy.

Preprint REVIEW | doi:10.20944/preprints202403.0892.v2

The Gut Connection: Exploring The Possibility Of Implementing Gut Microbial Metabolites in Lymphoma Treatment

Ahmad K. Al-Khazaleh, Dennis Chang, Gerald W. Münch, Deep Jyoti Bhuyan

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Lymphoma; Hodgkin’ s lymphoma; Non-Hodgkin’ s lymphoma; Burkitt lymphoma; gut microbiota; short-chain fatty acids; gut metabolites; postbiotics

Online: 18 March 2024 (09:32:30 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.0904.v1

Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia

Andrew Seto, Gregory Downs, Olivia King, Shabnam Salehi-Rad, Ana Baptista, Kayu Chun, Sylvie Grenier, Bevoline Nwachukwu, Mark David Minden, Adam Smith, Jose-Mario Capo-Chichi

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: acute leukemia; KMT2A patial tandem duplication (KMT2A-PTD); structural variation; optical genome mapping; next generation sequecing; multiplex-ligation probe amplication; OGM; NGS; MLPA

Online: 18 March 2024 (01:26:18 CET)

Show abstract| Download PDF| Share

Background. Gene rearrangements affecting KMT2A are frequent in acute myeloid leukemia (AML) and are often associated with a poor prognosis. KMT2A gene fusions are often detected by chromosome banding analysis and confirmed by fluorescence in-situ hybridization. However, small intragenic insertions, termed KMT2A partial tandem duplication (PTD), are particularly challenging to detect using standard molecular and cytogenetic approaches. Methods. We have validated the use of a custom hybrid capture based next-generation sequencing (NGS) panel for comprehensive profiling of AML patients seen at our institution. This NGS panel targets the entire consensus coding DNA sequence of KMT2A; to deduce the presence of a PTD we used the relative ratio of KMT2A exons coverage. We sought to corroborate the KMT2A-PTD NGS results using (1) multiplex-ligation probe amplification (MLPA) and (2) optical genome mapping (OGM). Results. We analyzed 932 AML cases and identified 41 individuals harboring a KMT2A-PTD. MLPA, NGS and OGM confirmed the presence of a KMT2A-PTD in 22 of the cases analyzed where orthogonal testing was possible. Two false positive PTD calls by NGS could be explained by the presence of cryptic structural variants impacting KMT2A and interfering with PTD analysis. OGM revealed the nature of these previously undetected gene rearrangements in KMT2A, while MLPA yielded in-conclusive results. MLPA analysis for KMT2A-PTD is limited to exon 4, whereas NGS and OGM resolved KMT2A-PTD sizes and copy number levels. Conclusion. KMT2A-PTDs are complex gene rearrangements that cannot be fully ascertained using a single genomic platform. MLPA, NGS panels and OGM are complementary technologies applied in standard of care testing for AML patients. MLPA and NGS panels are designed for targeted copy number analysis; however, our results show that integration of concurrent genomic alterations is needed for accurate KMT2A-PTD identification. Unbalanced chromosomal rearrangements overlapping with KMT2A can interfere with the diagnostic sensitivity and specificity of copy number based KMT2A-PTD detection methodologies.

Preprint ARTICLE | doi:10.20944/preprints202403.0879.v1

A Cost-Effective Predicting Model for Recurrent Gastric Cancer by Clinical Features

Chun-Chia Chen, Wen-Chien Ting, Hsi-Chieh Lee, Chi-Chang Chang, Tsung-Chieh Lin, Shun-Fa Yang

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Recurrent Gastric Cancer, Random Forest, SMOTE, SHAP, Cost-Sensitive Learning

Online: 15 March 2024 (10:41:57 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202403.0892.v1

The Gut Connection: Exploring The Possibility Of Implementing Gut Microbial Metabolites in Lymphoma Treatment

Ahmad K. Al-Khazaleh, Dennis Chang, Gerald W. Münch, Deep Jyoti Bhuyan

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Lymphoma; Hodgkin’s lymphoma; Non-Hodgkin’s lymphoma; Burkitt lymphoma; gut microbiota; short-chain fatty acids; gut metabolites; postbiotics

Online: 15 March 2024 (07:50:02 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202403.0902.v1

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)

Teresa Del Giudice, Nicoletta Staropoli, Pierfrancesco Tassone, Pierosandro Tagliafeerri, Vito Barbieri

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: NSCLC; lung cancer; gut microbiota; immunotherapy; immune checkpoint inhibitors

Online: 15 March 2024 (07:33:31 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.0670.v1

Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital

Inbal Dona Amar, Gianluca Franceschini, Camilla Nero, Ilaria Pasqua, Ida Paris, Armando Orlandi, Stefania Gori, Alessandra Fabi, Giorgia Garganese, Giovanni Scambia, Paola Villa

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Breast Cancer; Clinical Pathways; Menopause; Osteoporosis; Patient Care Management

Online: 12 March 2024 (08:01:05 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.0610.v1

Effects of Recombinant α1-Microglobulin on Early Proteomic Response in Risk Organs after Exposure to 177Lu-Octreotate

Charlotte Ytterbrink, Emman Shubbar, Toshima Z Parris, Britta Langen, Malin Druid, Emil Schüler, Sven Erik Strand, Bo Åkerström, Magnus Gram, Khalil Helou, Eva Forssell-Aronsson

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: A1M; antioxidant; proteomics; radio-protector; kidney; bone marrow; PRRT

Online: 11 March 2024 (21:46:26 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint REVIEW | doi:10.20944/preprints202403.0644.v1

PARP-Targeted Radiotheranostics with Auger Electrons: an Updated Overview

Luca Filippi, Luca Urso, Laura Evangelista

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Auger electrons; radionuclide therapy; prostate cancer; triple negative breast cancer; glioblastoma

Online: 11 March 2024 (18:03:21 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.0593.v1

Effectiveness of Atezolizumab in Metastatic Large Cell Neuroendocrine Carcinoma of the Lung and the Predictive Value of miR-375. The LANCE Trial, a Pilot Study

Georgios Evangelou, Ioannis P. Trontzas, Ioannis Gkiozos, Ioannis Vamvakaris, Maria Grammoustianou, Christina Paraskeva, Georgia Gomatou, Ioannis Tsamis, Ioannis A. Vathiotis, Maximilian Anagnostakis, Vasiliki Koliaraki, Konstantinos Syrigos

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: large cell neuroendocrine carcinoma; LCNEC; immunotherapy; atezolizumab; miR375

Online: 11 March 2024 (17:49:38 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202403.0544.v1

Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers

Crystal L Seales, Dhruv Puri, Nuphat Yodkhunnatham, Kshitij Pandit, Kit Yuen, Sarah Murray, Jane Smitham, John T Lafin, Aditya Bagrodia

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Germ Cell Tumors; Biomarkers; Serum Tumor Markers; miRNAs

Online: 10 March 2024 (17:02:36 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.0522.v1

Replies to Queries in Gynecologic Oncology by Bard, Bing and the Google Assistant

Edward J. Pavlik, Dharani Ramaiah, Taylor Rives, Allison Swiecki-Sikora, Jamie Land

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: accuracy; virtual assistants; Google; Google Bard/Gemini; Microsoft Bing-Copilot; gynecologic; oncology

Online: 8 March 2024 (14:42:50 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.0490.v1

A Multidisciplinary Hyper-Modeling Scheme in Personalized In Silico Oncology: Coupling Cell Kinetics With Metabolism, Signaling Networks and Biomechanics As Plug-In Component Models of a Cancer Digital Twin

Eleni Kolokotroni, Daniel Abler, Alokendra Ghosh, Eleftheria Tzamali, James Grogan, Eleni Georgiadi, Philippe Büchler, Ravi Radhakrishnan, Helen Byrne, Vangelis Sakkalis, Katerina Nikiforaki, Ioannis Karatzanis, Nigel J.B. McFarlane, Djibril Kaba, Feng Dong, Rainer M. Bohle, Eckart Meese, Norbert Graf, Georgios Stamatakos

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: in silico medicine; in silico oncology; cancer; hypermodeling; digital twin; virtual twin; computational oncology; Wilms tumor; non small cell lung cancer

Online: 8 March 2024 (04:11:35 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202403.0456.v1

DNA Damage Responses in Tumors Are Not Proliferative Stimuli but Rather They Are DNA Repair Actions Requiring Supportive Medical Care

Zsuzsanna Suba

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: antiestrogen; cancer therapy; estrogen; DNA damage; DNA damage response; DNA repair; endocrine disruptor; estrogen receptor; growth factor receptor; mutation

Online: 7 March 2024 (14:19:55 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202403.0378.v1

The Triple ASCs–Exosomes [T.A.E.] Technology to control the invasion of the Triple–Negative Breast Cancer towards the surrounding tissues

Andrea Pagani, Dominik Duscher, Sebastian Geis, Silvan Klein, Leonard Knoedler, Adriana C. Panayi, Dmytro Oliinyk, Oliver Felthaus, Lukas Prantl

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Extracellular vesicles; Exosomes; Triple - negative Breast cancer; T.A.E. Technology; Adipose-derived Stem Cells; Tumor Microenvironment

Online: 7 March 2024 (09:50:48 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.0385.v1

Consistency and Quality of ChatGPT Responses Compared to Clinical Guidelines for Ovarian Cancer: A Delphi Approach.

Dario Piazza, Federica Martorana, Annabella Curaba, Daniela Sambataro, Maria Rosaria Valerio, Alberto Firenze, Basilio Pecorino, Paolo Scollo, Vito Chiantera, Giuseppe Scibilia, Paolo Vigneri, Vittorio Gebbia, Giuseppa Scandurra

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: artificial intelligence; ChatGPT; ovarian carcinoma; guidelines

Online: 7 March 2024 (09:48:59 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.0432.v1

DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines

Matthew J Schniederjan, Cahil Potnis, Varshini Vasudevaraja, Catherine D Moser, Bethany Watson, Matija Snuderl, Tobey MacDonald, Beverly B. Rogers

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: DNA methylation; H3 K27M; cell culture; diffuse midline glioma; DIPG

Online: 7 March 2024 (09:17:01 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202403.0157.v1

Spotlight on New Hallmarks of Drug-Resistance towards Personalized Care for Epithelial Ovarian Cancer

Simona Frezzini, Sara Lonardi

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: epithelial ovarian cancer; drug-resistance; biomarkers

Online: 6 March 2024 (04:22:31 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint ARTICLE | doi:10.20944/preprints202403.0251.v1

Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model

Arman Romiani, Daniella Pettersson, Nishte Rassol, Klara Simonsson, Hana Bakr, Dan Emil Lind, Aniko Kovacs, Johan Spetz, Ruth H Palmer, Bengt Hallberg, Khalil Helou, Eva Forssell-Aronsson

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Neurobastoma; Radionuclide therapy; Apoptosis; Somatostatin analog; Radiosensitization; Combination therapy

Online: 5 March 2024 (13:05:37 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202403.0254.v1

Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts

Tomas Koltai, Larry Fliegel

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: dichloroacetate; cancer; lactic acidosis; glioma; pyruvate dehydrogenase kinase; pyruvate dehydrogenase; pyruvate dehydrogenase phosphatase

Online: 5 March 2024 (13:03:15 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202403.0108.v1

Radiotherapy for Metastatic Epidural Spinal Cord Compression with Increased Doses: Final Results of the RAMSES-01 Trial

Dirk Rades, Darejan Lomidze, Natalia Jankarashvili, Fernando Lopez Campos, Arturo Navarro-Martin, Barbara Segedin, Blaz Groselj, Christian Staackmann, Charlotte Kristiansen, Kristopher Dennis, Steven E. Schild, Jon Cacicedo

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: metastatic epidural spinal cord compression; highly-conformal radiotherapy; increased doses; phase 2 trial; historical control group; local progression-free survival

Online: 4 March 2024 (06:01:20 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202402.1720.v1

Lymph-Nodal Oligometastases from Prostate Cancer: Different Outcomes and Pattern of Relapse between Pelvic and Para-Aortic Disease

Edoardo Pastorello, Luca Nicosia, Luca Triggiani, Francesco Frassine, Paola Vitali, Emiliano Salah El Din El Tantawy, Valeria Santoro, Michele Rigo, Simona Gaito, Renzo Mazzarotto, Michela Buglione di Monale e Bastia, Filippo Alongi

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: SBRT; oligometastases; prostate cancer; SABR

Online: 29 February 2024 (13:09:45 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202402.1586.v1

Low-Volume Metastases in Cervical Cancer: Does Size Matter?

Tommaso Bianchi, Tommaso Grassi, Giampaolo Di Martino, Serena Negri, Gaetano Trezzi, Robert Fruscio, Fabio Landoni

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: cervical cancer; low-volume metastases; micrometastases; isolated tumor cells; ultrastaging; sentinel lymph node

Online: 27 February 2024 (19:22:39 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202402.1521.v1

Effect of Neoadjuvant Chemotherapy on Tumor Infiltrating Lymphocytes in Resectable Gastric Cancer: Analysis from a Western Academic Center

Elliott J Yee, Danielle Gilbert, Jeffrey Kaplan, Sachin Wani, Sunnie S Kim, Martin D McCarter, Camille L Stewart

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: gastric cancer, tumor infiltrating lymphocytes, neoadjuvant therapy, immunotherapy

Online: 27 February 2024 (09:28:15 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint REVIEW | doi:10.20944/preprints202402.1493.v1

Real-World Data and Evidence in Lung Cancer: A Review of Recent Developments

Eleni Kokkotou, Maximilian Anagnostakis, Georgios Evangelou, Nikolaos K Syrigos, Ioannis Gkiozos

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: oncology; real-world data; real-world evidence; epidemiology; safety; efficacy; artificial intelligence; machine learning; data quality; lung cancer

Online: 27 February 2024 (08:04:33 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202402.1485.v1

Oro-Facial Metastases from Renal Cell Carcinoma: A Systemic Review of the Literature with Focus on the Clear Cell Variant

Vanja Granberg, Alessandra Laforgia, Marta Forte, Daniela Di Venere, Gianfranco Favia, Chiara Copelli, Alfonso Manfuso, Giuseppe Ingravallo, Antonio D'Amati, Saverio Capodiferro

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: metastates; renal cell carcinoma; clear cell renal carcinoma; oral cavity; head and neck

Online: 26 February 2024 (15:50:00 CET)

Show abstract| Download PDF| Share

Background: Metastatic tumors to the oro-facial tissues are rare, with an incidence ranging between 1% and 8% of all oral malignant tumors. Generally reported with a peak of incidence in the 5th–7th decades, but possibly occurring at any age, metastases may represent the first sign of an occult cancer or manifest in patient with an already known history of a primary carcinoma, mostly from the lungs, kidney, prostate, and colon-rectum in males, or uterus, breast, lung, and ovary in females. In the oro-facial tissues the sites mostly involved are the oral mucosa, gingiva/jawbones, tongue, and the salivary glands. Methods: A systemic Review of the literature on the oro-facial metastases from Renal Cell Carcinoma has been conducted by searching the most used databases, also focusing the attention on the Clear Cell histological variant, representing the most frequent one. Results: Among the 160 analyzed studies, 211 cases of oral metastases of renal cancer were found (148 in males, 70.1%; 63 in females, 29.8%), with an average age of 59.8 years. In almost 40% of cases, metastasis represented the first clinical manifestation of the primary tumor and 122 were histologically diagnosed as ccRCCs (57.8%). The tongue was involved in most of the cases (26% - 55 cases), followed by mandible (18.9% - 40 cases), gingiva (18.4% - 39 cases), maxilla (10.9% - 23 cases), parotid gland (10.4% - 22 cases), buccal mucosa (5.2% - 11 cases), lips (3.3% - 7 cases), hard palate (2.8% - 6 cases), soft palate, masticatory space and submandibular gland (0.9% - 2 cases), lymph nodes, tonsil and oral floor (0.4% - 1 case). Among the 122 ccRCCs (84 were males, 68.8 %; 38 females, 31.1%), with an average age of 60.8 years and representing in 33.6% the first clinical manifestation, the tongue remained the most involved site (25.4% - 31 cases), followed by the gingiva (17.2% - 21 cases), parotid gland (13,1% - 16 cases), mandibular bone (12.2% - 15 cases), maxillary bone (11.4% - 14 cases), buccal mucosa and lips (4.9% - 6 cases), hard palate (4% - 5 cases), submandibular gland and soft palate (1.6% - 2 cases), lymph nodes, tonsil, oral floor and masticatory space (0.8%. 1 case). The clinical presentation in soft tissues was represented by a fast-growing exophytic mass, sometimes accompanied by pain. Instead inn bone appeared as radiolucent lesions, with ill-defined borders and cortical erosion. Conclusions: Our data focus the attention on the incidence of Renal cancer Metastases in the oro-facial tissues. Their early identification surely represents a diagnostic challenge, especially when the clinical work-up is limited to the cervico-facial region. Nevertheless, early diagnosis and recently introduced adjuvant therapies may represent the key for better outcomes. Therefore, general guidelines about clinical and radiological identification of oro-facial potentially malignant lesions should be part of the cultural background of any dentists.

Preprint ARTICLE | doi:10.20944/preprints202402.1464.v1

Analysis of CDO, PITX2, and CDH13 gene methylation in early endometrial cancer for prediction of medical treatment outcomes

Aleksey M. Krasnyi, Lyubov T. Gadzhieva, Diana N. Kokoeva, Mark G. Kosenko, Ekaterina L. Yarotskaya, Stanislav V. Pavlovich, Levon A. Ashrafyan, Gennady Sukhikh

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: methylation; atypical endometrial hyperplasia; endometrial cancer; organ-preserving treatment; MS-HRM; CDO1; CDH13

Online: 26 February 2024 (14:19:49 CET)

Show abstract| Download PDF| Share

An observational cohort study of patients diagnosed with endometrial cancer (EC) stage IA G1, or atypical endometrial hyperplasia (AHE), undergoing organ-preserving treatment, was conducted. Objective of the study: to determine CDO1, PITX2, and CDH13 gene methylation levels in early endometrial cancer and atypical hyperplasia specimens obtained before organ-preserving treatment in the patients with adequate response and with insufficient response to hormonal treatment. Materials and methods: 41 endometrial specimens obtained during diagnostic uterine curettage in women with EC (n=28) and AEH (n=13), willing to preserve reproductive function, were studied; 18 specimens of endometrial cancer IA stage G1 from peri- and early postmenopausal women (comparison group) were included in the study. The control group included 18 endometrial specimens from healthy women obtained by diagnostic curettage for missed abortion and/or intrauterine adhesions. Methylation levels were analyzed using the modified MS-HRM method. Results: All 13 women with AEH had complete response (CR) to medical treatment. In the group undergoing organ-preserving treatment for uterine cancer IA stage G1 (n=28), 14 patients had complete response (EC CR group) and 14 had not (non-CR). It was found that all groups had statistically significant differences in CDO1 gene methylation levels with the control group (p<0.001) except for the EC CR group (p=0.21). The p-value of difference between EC CR and EC non-CR groups was <0.001. The differences in PITX2 gene methylation levels between the control and study groups were also significantly different (p<0.001), except for AEH group (p=0.21). For the difference between EC CR and EC non-CR groups, the p-value was 0.43. For CDH13 gene methylation levels, statistically significant differences were found between the control and EC non-CR groups (p<0.001), and the control and EC comparison groups (p=0.005). When comparing the EC CR group with EC non-CR group, the p-value for this gene was <0.001. Simultaneous assessment of CDO1 and CDH13 genes methylation allowed to accurately distinguish between EC CR and EC non-CR groups (AUC=0.96). Conclusion: Assessment of CDO1 and CDH13 gene methylation in endometrial specimens from patients with endometrial cancer (IA stage G1), planned for medical treatment, can predict the treatment outcome.

Preprint REVIEW | doi:10.20944/preprints202402.1401.v1

3-D structure of Novel Liver Cancer Biomarker LC-SPIK and its Performance in Clinical Diagnosis of HCC

Xuanyong Lu, Felix Lu, Connor Ott, Prabha Bista

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Biomarker; HCC (Hepatocellular Carcinoma); LC-SPIK (Liver Cancer specific Serine Protease Inhibitor Kazal); AFP (Alpha-Fetoprotein); NAFLD (nonalcoholic fatty liver disease)

Online: 26 February 2024 (12:01:59 CET)

Show abstract| Download PDF| Share

LC-SPIK is a liver cancer-specific isoform of Serine Protease Inhibitor Kazal and has been proposed as a new biomarker for the detection of HCC given its unique 3-D structure which differs from normal pancreatic SPIK. An ELISA technology based on its unique structure was developed to use LC-SPIK as an effective biomarker for the clinical diagnosis of HCC. AFP, the most widely used biomarker for HCC surveillance currently, suffers from poor clinical performance, especially in the detection of early-stage HCC. In one case-control study, which included 164 HCC patients and 324 controls, LC-SPIK had an AUC of 0.87 compared to only 0.70 for AFP in distinguishing HCC from liver disease controls (cirrhosis, HBV/HCV). LC-SPIK also performed significantly better than AFP for the 81 patients with early-stage HCC (BCLC stage 0 and A), with an AUC of 0.85 compared to only 0.61 for AFP. Cirrhosis is the major risk factor for HCC, about 80% of patients with newly diagnosed HCC have preexisting cirrhosis. LC-SPIK’s clinical performance was also studied in HCC patients with viral and non-viral cirrhosis including cirrhosis caused by nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). In a total of 163 viral cirrhosis patients with 93 HCC patients (50 early-stage), LC-SPIK had an AUC of 0.85, while AFP had an AUC of 0.70. For patients with early-stage HCC, LC-SPIK had a similar AUC of 0.83, while AFP had an AUC of only 0.60. For 120 patients with nonviral cirrhosis, including 62 HCC (23 early-stage) patients, LC-SPIK had an AUC of 0.84 while AFP had an AUC of only 0.72. For the 23 patients with early-stage HCC, LC-SPIK had a similar AUC of 0.83, while the AUC for AFP decreased to 0.65. All these results suggest that LC-SPIK has significantly better performance in the detection of HCC than AFP in all etiologies of liver diseases. In addition, LC-SPIK accurately detected the presence of HCC in 71%-91% of HCC patients with false-negative AFP test results in viral associated HCC and non-viral associated HCC.

Preprint COMMUNICATION | doi:10.20944/preprints202402.1423.v1

Exploring the Combined Action of Adding Pertuzumab to the Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

Emma Franco-Mateos, Virginia Souza-Egipsy, Laura García-Estévez, Jose Manuel Perez-García, Maria Gion, Laia Garrigós, Patricia Cortez, Cristina Saavedra, Patricia Gómez, Carolina Ortiz, Victor L. Cruz, Javier Ramos, Javier Cortés, Juan F. Vega

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: HER2+ breast cancer, monoclonal antibodies, trastuzumab biosimilars.

Online: 26 February 2024 (10:20:30 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint REVIEW | doi:10.20944/preprints202402.1410.v1

Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation

Weiyuan Wang, Melanie Cristina Lopez McDonald, Rajashree Hariprasad, Tiara Hamilton, David A. Frank

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: STAT3; STAT5; cancer, immunity, cancer therapy

Online: 26 February 2024 (09:40:00 CET)

Show abstract| Download PDF| Share

Preprint HYPOTHESIS | doi:10.20944/preprints202402.1404.v1

Exploring the Potential Use of Natural Products Together with Alkalization in Cancer Therapy

Masahide Isowa, Reo Hamaguchi, Ryoko Narui, Hiromasa Morikawa, Toshihiro Okamoto, And Hiromi Wada

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: tumor microenvironment; alkalization therapy; natural products; cancer, complementary and alternative medicine

Online: 26 February 2024 (09:30:46 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202402.1208.v1

Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status

Sanghyun An, Wanlu Li, Hyejin Do, Hye Youn Kwon, Bora Kim, Kwangmin Kim, Youngwan Kim, Mee-Yon Cho

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: colorectal neoplasms; microsatellite instability; immune checkpoint proteins; immunotherapy

Online: 21 February 2024 (15:00:37 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202402.1168.v1

Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO)

Tibor A. Zwimpfer, Esra Bilir, Khayal Gasimli, Andrej Cokan, Nicolò Bizzarri, Zoia Razumova, Joanna Kacperczyk-Bartnik, Tanja Nikolova, Andrei Pletnev, Ilker Kahramanoglu, Aleksander Shushkevich, Aleksandra Strojna, Charalampos Theofanakis, Tereza Cicakova, Marcus Vetter, Céline Montavon, Gilberto Morgan, Viola Heinzelmann-Schwarz

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Desensitization; Platinum; Taxane; Hypersensitivity reaction; Gynecologic cancer; Chemotherapy

Online: 20 February 2024 (16:43:17 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202402.1099.v1

Dendritic Cells Immunotherapy of Ovarian Cancer: Overview of Our Achievements

Jiřina Bartůňková

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: ovarian cancer; dendritic cells; immunotherapy; tumor microenvironment

Online: 20 February 2024 (07:05:17 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202402.1049.v1

True Benefits of Immune Checkpoint Inhibitors in the Treatment of Malignant Pleural Mesothelioma in Japan

Kozo Kuribayashi, Jun Hirano

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: malignant pleural mesothelioma; immune checkpoint inhibitor; orphan drug; good clinical practice; Pharmaceuticals and Medical Devices Agency

Online: 20 February 2024 (04:03:22 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202402.1056.v1

Performance of the Wisconsin Card Sorting Test in Oncopediatric Patients in an Oncology Unit in Cali, Colombia: A Cross-Sectional Observational Study

Ángela María Jiménez, Valeria Santa, Manuel Guerrero, Angie Carolina Guerrero Benitez, Tania Romo-González, Alejandro Botero Carvajal

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Wisconsin Card Sorting Test; oncology; neuropsychology assessment; executive function; pediatrics.

Online: 19 February 2024 (11:52:36 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202402.0976.v1

The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer

Klaudia Żak, Małgorzata Satora, Ilona Skrabalak, Rafał Tarkowski, Marta Ostrowska-Leśko, Marcin Bobiński

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: bevacizumab; ovarian cancer; angiogenesis; VEGF

Online: 19 February 2024 (11:19:20 CET)

Show abstract| Download PDF| Share

Preprint CASE REPORT | doi:10.20944/preprints202402.0935.v1

Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features

Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, Masakazu Sano, Haruko Iwabuchi, Nao Shibata, Masaru Imamura, Chihaya Imai, Hirokazu Takami, Koichi Ichimura, Ryo Nishikawa, Hajime Umezu, Akiyoshi Kakita, Makoto Oishi

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: growing teratoma syndrome; multimodal treatment; methylation classifier; copy number variation analysis

Online: 19 February 2024 (10:25:15 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202402.0888.v1

Impact of the COVID-19 Pandemic on the Diagnosis of Malignant Neoplasia of the Bronchus and Lung in the Burgos Region

Fernando G. Gutierrez-Herrero, Sandra Núñez-Rodríguez, Carla Collazo, Álvaro García-Bustillo, Mirian Santamaría-Peláez, Jerónimo J. González-Bernal, Josefa González-Santos

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: malignant lung neoplasia; Covid-19; pandemic; diagnosis; survival.

Online: 16 February 2024 (07:04:29 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202402.0830.v1

A Descriptive Study of 103 Primary Cutaneous B-cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (Gotel)

Natividad Martínez-Banaclocha, Francisca Martínez-Madueño, Berta Caballé, Joan Badia, Mar Blanes, David Aguiar Bujanda, Virginia Calvo, Jose Gomez Codina, Cristina Quero Blanco, Pablo Espinosa, Javier Lavernia, Francisco Ramón García Arroyo, María Guirado Risueño, Cristina Llorca, Raquel Cumeras, Mariano Provencio Pulla, Josep Gumà

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: cutaneous B lymphoma; skin; surgery; radiotherapy; chemotherapy; rituximab

Online: 15 February 2024 (09:29:20 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint ARTICLE | doi:10.20944/preprints202402.0773.v1

Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement

Sandeep Sehdev, Nigel S. B. Rawson, Olexiy I. Aseyev, Catriona J. Buick, Marcus Butler, Scott Edwards, Sharlene Gill, Joanna Gotfrit, Cyrus C Hsia, Rosalyn A. Juergens, Mita Manna, Joy McCarthy, Som D. Mukherjee*, Stephanie Snow, Silvana Spadafora, David J. Stewart, Jason Wentzell, Ralph P.W Wong, Pawel Zalewski

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: oncology drugs; health technology assessment; drug prices; drug access; Canada

Online: 14 February 2024 (05:27:56 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202402.0676.v1

Microbiome Dysbiosis Associates to Castration Resistance and Cancer Stemness in Metastatic Prostate Cancer

Matthew Uzelac, Ruomin Xin, Weg M. Ongkeko

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: prostate cancer; castration-resistant prostate cancer; microbiome; cancer stem cells

Online: 12 February 2024 (10:44:58 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202402.0668.v1

Myelodysplastic Neoplasms (MDS): A Narrative Review from the Era of Precision Medicine

Daniel Karel, Claire Valburg, Navitha Woddor, Victor Nava, Anita Aggarwal

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Myelodysplastic neoplasm; myelodysplastic syndrome; MDS; precision medicine; targeted therapy

Online: 12 February 2024 (10:29:30 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202402.0609.v1

Lung NETs and GEPNETs: One Cancer with Different Origins or Two Distinct Cancers?

Georgios Evangelou, Ioannis Vamvakaris, Anastasia Papafili, Maximilian Anagnostakis, Melpomeni Peppa

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Lung NETs, neuroendocrine tumors, typical carcinoid, atypical carcinoid, pulmonary NETs, EGFR, DLL3, immunotherapy

Online: 12 February 2024 (09:53:33 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202401.0886.v2

Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study)

Noritoshi Kobayashi, Yasuhiro Yabushita, Ryutaro Mori, Tomoaki Takahashi, Kentaro Miyake, Yu Sawada, Yuki Homma, Ryusei Matsuyama, Naoki Okubo, Eriko Katsuta, Kensuke Kubota, Shoji Yamanaka, Yasushi Ichikawa, Itaru Endo

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: unresectable locally advanced pancreatic cancer; FOLFIRINOX; R0 resection

Online: 9 February 2024 (11:16:19 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202402.0535.v1

Non-mutational Key Features in the Biology of Thymomas

Stefan Küffer, Denise Müller, Alexander Marx, Philipp Ströbel

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Thymus; thymoma; oncogenic driver; mutations; chromosomal aberrations; RNA; methylation; gene expression; apoptosis; proteomics, metabolomics

Online: 9 February 2024 (08:17:34 CET)

Show abstract| Download PDF| Share

Preprint ARTICLE | doi:10.20944/preprints202402.0487.v1

Hypermethylated Colorectal Cancer Patients Present a Myc-Driven Hypermetabolism with a One-Carbon Signature Associated to Worsen Prognosis

Christophe Desterke, Emmanuel Dornier

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Myc; metabolism; colorectal cancer; CIMP; immunotherapy; one-carbon metabolism

Online: 8 February 2024 (10:03:57 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint ARTICLE | doi:10.20944/preprints202402.0415.v1

Discovery of Two Targets of Dexmedetomidine in Breast Cancer

Jie Luo

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: triple-negative breast cancer; dexmedetomidine; IDO1; CHRM3

Online: 7 February 2024 (08:18:40 CET)

Show abstract| Download PDF| Share

Background: As the most invasive breast cancer (BrCa), triple-negative BrCa (TNBC) has the worst survival. The use of dexmedetomidine potentially affected BrCa surgery and dexmedetomidine was reported to have direct effects on TNBC cells. The objective of this study is to explore the mechanisms underlying the effect of dexmedetomidine on TNBC. Methods: Dexmedetomidine targets were predicted using The Cancer Genome Atlas data SwissTargetPrediction. Cell lines MDA-MB-231, MCF7, and MCF10A were used to validate the targets in TNBC with both clinical samples and cell lines. Cancer cell lines and normal breast cell lines were grouped in cancer and normal groups respectively. Both groups were exposed to dexmedetomidine treatment. Cell Counting Kit-8 was used to determine the effect of dexmedetomidine on cells with target silencing. The binding model of the candidate targets was docked and critical amino acids were mutated to validate the binding model. Results: Dexmedetomidine selectively inhibits cancer cells. Catalytic subunit of the DNA-dependent protein kinase (PRKDC), indoleamine 2,3-dioxygenase 1 (IDO1), opioid receptor kappa 1 (OPRK1), glutaminyl-peptide cyclotransferase (QPCT), macrophage migration inhibitory factor (MIF), potassium voltage-gated channel, subfamily H (Eag-related), member 2 (KCNH2), cholinergic receptor, muscarinic 3 (CHRM3), and potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 (KCNN4) were identified as dexmedetomidine targets in TNBC. The expression levels of PRKDC, IDO1, MIF, KCNH2, CHRM3, and KCNN4 were found to be upregulated in TNBC tissues compared to non-TNBC tissues(p<0.05). Silencing of these genes was found to reduce the sensitivity of TNBC cells to dexmedetomidine(p<0.05). This effect was counteracted when the silenced genes were overexpressed, resulting in an increase in the sensitivity of cells to dexmedetomidine (p<0.05). Furthermore, a direct interaction between dexmedetomidine and IDO1 and CHRM3 was observed, which regulated the sensitivity of cells to dexmedetomidine(p<0.05).Conclusion: IDO1 and CHRM3 are direct targets of dexmedetomidine in TNBC.

Preprint ARTICLE | doi:10.20944/preprints202402.0355.v1

Single-Cell Profiling Reveals Immune-Based Mechanisms Underlying the Tumor Radiosensitization by a Novel Mn Porphyrin Clinical Candidate, MnTnBuOE-2-PyP⁵⁺ (BMX-001)

Sun Up Noh, Jinyeong Lim, Sung-Won Shin, Yeeun Kim, Woong-Yang Park, Ines Batinic-Haberle, Changhoon Choi, Won Park

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Mn porphyrin clinical candidate, MnTnBuOE-2-PyP⁵⁺ (BMX-001, MnBuOE); Single-cell RNA sequencing; Tumor heterogeneity; Tumor microenvironment; Radiotherapy; Tumor radiosensitization

Online: 6 February 2024 (09:43:28 CET)

Show abstract| Download PDF| Supplementary Files| Share

Preprint ARTICLE | doi:10.20944/preprints202402.0260.v1

Devising Breast Cancer Diagnosis Protocol through Machine Learning

Tooba Mujtaba

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: Estrogen Receptor; Progestrone Receptor; Human epidermal growth factor Receptor

Online: 5 February 2024 (15:21:45 CET)

Show abstract| Download PDF| Share

Preprint REVIEW | doi:10.20944/preprints202308.1536.v4

Addendum and Non-invasive Multiregion, Multisample Tumor Sequencing

Michael Renteln

Subject: Medicine And Pharmacology, Oncology And Oncogenics Keywords: multiregion sequencing; multisample sequencing; targeted cancer therapy; OVERCOME; macrophage magnetotaxis

Online: 5 February 2024 (13:52:59 CET)

Show abstract| Download PDF| Share

Medicine and Pharmacology